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a b s t r a c t
Glucocorticoids (GCs) cause cell cycle arrest and apoptosis in lymphoid cells which is exploited to treat
lymphoid malignancies. The mechanisms of these anti-leukemic GC effects are, however, poorly under-
stood. We previously deﬁned a list of GC-regulated genes by expression proﬁling in children with acute
lymphoblastic leukemia (ALL) during systemic GC monotherapy and in experimental systems of GC-
induced apoptosis. PLZF/ZBTB16, a transcriptional repressor, was one of the most promising candidates
derived from this screen. To investigate its role in the anti-leukemic GC effects, we performed overex-
pression and knock-down experiments in CCRF-CEM childhood ALL cells. Transgenic PLZF/ZBTB16 alone
had no detectable effect on cell proliferation or survival, but reduced sensitivity to GC-induced apoptosis
but not apoptosis induced by antibodies against Fas/CD95 or 3 different chemotherapeutics. Knock-unctional gene analysis
lucocorticoid-induced apoptosis
LZF/ZBTB16
down of ZBTB16 entailed a small, but signiﬁcant, increase in cell death induction by GC. Affymetrix Exon
array-based whole genome expression proﬁling revealed that PLZF/ZBTB16 induction did not signiﬁ-
cantly alter the expression proﬁle, however, it interfered with the regulation of numerous GC response
genes, including BCL2L11/Bim, which has previously been shown to be responsible for cell death induc-
tion in CCRF-CEM cells. Thus, the protective effect of PLZF/ZBTB16 can be attributed to interference with
by Gtranscriptional regulation
. Introduction
Glucocorticoids (GCs) induce apoptosis in certain cells of the
ymphoid lineage and are therefore useful therapies in the treat-
ent of lymphoid malignancies, most notably childhood acute
ymphoblastic leukemia (ALL) [1]. GCs mediate their effects via
he GC receptor (GR), a ligand-activated transcription factor of
he nuclear receptor super-family that resides in the cytoplasm
nd, upon ligand binding, translocates into the nucleus, where it
odulates gene expression via binding to speciﬁc DNA responselements or by protein–protein interactions with other transcrip-
ion factors [2–5]. A large number of genes have been identiﬁed
hat are regulated by GCs in lymphoid lineage cells in experimental
ystems [6] and related clinical samples [7,8], but the genes respon-
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sible for cell death inductionandother effects ofGCson the immune
system are not well understood (for recent reviews see [6,9–12]).
One of the most interesting GC-regulated candidate genes iden-
tiﬁed in the above screen was ZBTB16 (zinc ﬁnger and BTB domain
containing gene 16), also referred to as promyelocytic leukemia
zinc ﬁnger (PLZF, reviewed in [13,14]). It was induced by GC in the
majority of children with precursor B-cell and T-cell ALL, in one
patient with adult ALL and in peripheral blood lymphocytes from
2 healthy donors treated with GC, but not in 2 ALL cell lines [7].
More recently, we re-analyzed these data using a normalization
procedure that better resolves regulations of low abundance genes
(GC-RMA) [15] and also performed additional expression proﬁling
studies of 14moreALL children (J. Rainer, in preparation) and found
that PLZF/ZBTB16 was induced by GC more than 2-fold in 23 of 27
such cases.
PLZF/ZBTB16 was initially identiﬁed as a fusion partner of
retinoic acid receptor  (RAR) in a variant chromosomal translo-
Open access under CC BY-NC-ND license. cation t(11;17)(q23;q21) that occurred in a subset of acute
promyelocytic leukemia patients [16,17]. PLZF/ZBTB16 is a tran-
scriptional repressor of the POK (POZ and Krüppel) family of
proteins. It contains one BTB (Broad complex, Tramtrack, and
Bric à brac)/POZ (poxviruses and zinc ﬁnger and Krüppel) domain
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t the NH2-terminal moiety and 9C2H2 Krüppel-type zinc ﬁn-
ers at the carboxy-terminal end of the protein. The POZ/BTB
omainmediates interactionswith proteins such as transcriptional
o-repressors entailing chromatin remodeling and transcriptional
ilencing. The Krüppel-type zinc ﬁngers confer speciﬁcity of the
epressor activity to particular promoters by interacting with
orresponding response elements in regulatory regions of genes
epressed by PLZF/ZBTB16 [18–21]. The hinge region of the
rotein contains a PEST domain with two consensus sites for
DK2-mediated phosphorylation that triggers ubiquitination and
ubsequent degradation of PLZF through the ubiquitin-proteasome
athway [22]. The human PLZF/ZBTB16 gene maps to chromosome
1q22–q23 with seven exons [23] distributed over a region of
pproximately 200kb. Although additional alternative transcripts
ncoding distinct proteins have been reported [24], most recent
CBI and Ensembl databases contain 2 and 3 transcripts, respec-
ively, that differ only in their 5′ untranslated region and thus
ncode the same protein.
Regarding its function, a natural mutation (luxoid) in, and
nock-out of, the mouse homologue Zfp145/ZBTB16 unraveled a
rucial role in limb and skeletal patterning and spermatogonial
tem cell maintenance [25–27]. PLZF/ZBTB16 has further been
mplicated in tumor suppression in melanoma [28] and prostate
ancer [29], ascribed to its ability to cause cell cycle arrest and
nduce apoptosis in certain cell systems. The complex effects of
LZF/ZBTB16 have been associated with transcriptional repression
f numerous genes such asmembers of theHox family of transcrip-
ion factors [25], kit [18], CRABPI [30], c-myc [31], CCNA2/Cyclin A,
DKN1B/p27/Kip1 [32] and possibly others [26,28,29,33,34]. Thus,
ts suggested role in cell cycle arrest and apoptosis induction in
ome systems [28,31,34,35], further supported a possible role of
LZF/ZBTB16 induction in the anti-leukemic GC response.
In this study, we extended our analysis of GC regulation of
LZF/ZBTB16 to several leukemic cell lines and performed func-
ional analyses on the role of PLZF/ZBTB16 in the anti-leukemic
ffects of GC. We found that transgenic PLZF/ZBTB16 alone had
o effect on cell proliferation and survival, but reduced sensitiv-
ty to apoptosis induced by the GC analogue dexamethasone in the
CRF-CEMmodel for T-ALL. Similarly, knock-down of PLZF/ZBTB16
n CCRF-CEM cells entailed a small, but signiﬁcant, increase in
ell death induction by dexamethasone. We further exploited
hole genome expression proﬁling to derive a molecular expla-
ation for the protective effect of PLZF/ZBTB16 on GC-induced
poptosis.
. Materials and methods
.1. Cell lines and tissue culture
The T-ALL cell lines CCRF-CEM-C7H2 [36], CEM-C7H2-2C8
37], a CEM-C7H2 derivative with constitutive expression of the
etracycline-regulated reverse transactivator, rtTA [38], MOLT4
CRL-1582, ATCC, Rockville, MD), and Jurkat (untransfected and
rat GR-transfected derivative [39]), the precursor B-cell lines
97/EU-3 (ACC 42, DSMZ, Braunschweig, Germany), NALM6 (ACC
28, DSMZ), RS4;11 (ACC 508, DSMZ) and AT-1[40] (kindly pro-
ided by R. Panzer Grümeier, Vienna), and the Burkitt’s lymphoma
audi (CCL-213, ATCC) were cultured in RPMI 1640 supplemented
ith10% fetal calf serumand2mM l-glutamineat 37 ◦C, 5% carbon-
ioxide and saturated humidity. HEK293T packaging cells (ATCC,
anassas, VA) were cultured in DMEM supplemented as above.
he cells were free of mycoplasma infection and their authentic-
ty was veriﬁed by DNA ﬁngerprinting, as detailed previously [41].
axol was dissolved in DMSO (10mg/ml), doxycycline (100g/ml)
n phosphate buffered saline, doxorubicin (10mg/ml) and mit-& Molecular Biology 120 (2010) 218–227 219
omycin C (500g/ml) in destilled water, and -dexamethasone
(10−4 M) in 100% ethanol. The ﬁnal ethanol-concentration in
the dexamethasone-treated and control cultures was main-
tained at 0.1%. All above reagents were from Sigma (Vienna,
Austria).
2.2. Apoptosis determinations and cell cycle analyses
Apoptosis was determined by FACS analysis of propidum iodide
(PI)-treated permeabilized cells [42], as previously detailed [43].
Even though this method may over-estimate the rate of apoptotic
cells as compared to othermethods, it allows simultaneous analysis
of cell death induction and cell cycle progression in the same sam-
ples. Moreover, since this study addresses whether PLFZ/ZBTB16
reduces or increases cell death, the absolute extent of apoptosis
does not affect its conclusions. Cells were analyzed with a FAC-
Scan cytometer (Becton Dickinson Biosciences, San Jose, CA) in
combination with CellQuest Pro software (Becton Dickinson Bio-
sciences) acquiring forward scatter/sideward scatter, FL-2 (log),
and FL-3 (linear). In FL-2, the percentage of nuclei with reduced
DNA-content (subG1 peak) was assessed. For cell cycle determi-
nation, the FACS data from PI-treated nuclei were analyzed using
ModFit LT 2.0 (Verity, Topsham, ME) with the following quality
parameters: minimal number of events analyzed: 10,000 and max-
imal %CV: 8. For the knock-down experiments, the percentage of
viable cells in culture was determined by staining cell suspensions
with 1g/ml 7-amino-actinomycinD (7-AAD; Sigma–Aldrich) plus
APC-coupled Annexin-V (Becton Dickinson) and analyzing the
samples in a FACScan (Becton Dickinson). Cells staining posi-
tive for Annexin-V and/or 7-AAD were deﬁned as undergoing cell
death.
2.3. Immunoblotting
Our immunoblotting procedure has been described in detail
recently [44]. Brieﬂy, proteins were extracted from 5×106 cells
in 100l RIPA-buffer, quantiﬁed by Bradford analysis, mixed with
40l loading buffer (4× SSB, 5% -mercaptoethanol), denatured,
fractionated on a 12.5% SDS-PAGE and electroblotted onto nitro-
cellulose. The membranes were incubated overnight with rabbit
polyclonal antibodies against PLZF/ZBTB16 (HPA001499, Prestige
antibodies, Sigma, Vienna, Austria) or BCL2L11/Bim (#559685, Bec-
ton Dickinson Biosciences, San Jose, CA), or mouse monoclonal
antibodies against-tubulin (DM1A, CalBiochem,Nottingham, UK)
as a loading control. Speciﬁcally bound antibodies were detected
withanti-rabbit or anti-mousehorseradish-peroxidase-conjugated
secondary antibodies (Amersham Pharmacia Biotech, Uppsala,
Sweden) and visualised by chemiluminescence (ECL, Amersham)
and subsequent exposure to AGFA Curix X-ray ﬁlms for 1 s to
30min.
2.4. Generation of CCRF-CEM derivatives with PLZF/ZBTB16
overexpression and RNAi-mediated knock-down
2.4.1. Constructs for gene overexpression and knock-down
The lentiviral conditional expression construct pHR-
tetCMV-ZBTB16 (U317) was generated using the GATEWAYTM
technology (Invitrogen, Carlsbad, CA). The details of this pro-
cedure and the generation of stable clonal cell lines with
tetracycline-regulated expression of cDNAs cloned into such
constructs has been described previously [45]. In brief,
human PLZF/ZBTB16 mRNA was PCR-ampliﬁed from IRAT
p970B0341D6 (RZPD, Germany) using forward primer 5′-
CAAAAAAGCAGGCTCCGCCACCATGGATCTGACAAAA-3′ and reverse
primer 5′-CAAGAAAGCTGGGTCTTACACATAGCACAGGTAGAGG-3′,
and (after a second PCR reaction to complete the attB sites) recom-
2 istry
b
(
r
G
T
s
(
g
s
t
H
s
B
c
v
1
p
2
s
a
p
n
P
t
c
C
d
c
g
c
a
e
2
5
M
a
P
B
a
R
t
s
t
a
1
t
P
a
t
i
L
c20 M. Wasim et al. / Journal of Steroid Biochem
ined into pDONR207 (Invitrogen) resulting in pENTR207-ZBTB16
U316). The construct was sequence-veriﬁed and subsequently
ecombined into the “destination vector” pHR-tetCMV-Dest-IRES-
FP (U192) to generate pHR-tetCMV-ZBTB16-ires-GFP (U317).
he lentiviral shRNA-expressing constructs pHR-THT-ZBTB16-
hRNA1-SFFV-GFP (U547), pHR-THT-ZBTB16-shRNA2-SFFV-GFP
U548) and pHR-THT-cocntrol-shRNA-SFFV-GFP (U288) were
enerated as described previously [45]. In brief, complementary
hRNA oligonucleotides directed against PLZF/ZBTB16 and a non-
arget nucleotide sequence (control shRNA) containing BamHI and
indIII sticky ends were synthesized (MWG Ebersberg, Germany)
equences:
shRNA1 (PLZF-Exon7/U547): 5′-GATCCCCGCCACAAGCCCGAGGA-
GATTTCAAGAGAATCTCCTCGGGCTTGTGGCTTTTTGGAAA-3′;
shRNA2 (PLZF-Exon6; U548): 5′-GATCCCCCATCCACACGGGTGAG-
AAATTCAAGAGATTTCTCACCCGTGTGGATGTTTTTGGAAA-3′;
control shRNA (U288): 5′-GATCCCCGTATCATCTCTTGAA-
TGATTTCAAGAGAATCATTCAAGAGATGATACTTTTTGGAAA-3′).
The annealed oligonucleotides were cloned into the
glII–HindIII sites of pENTR-THT (U191) and the THT-shRNA
assette was recombined into the lentiviral RNAi “destination”
ector pHR-Dest-SFFV-eGFP (U218) to generate pHR-THT-shRNA-
-SFFV-GFP (U547), pHR-THT-shRNA-2-SFFV-GFP (U548) and
HR-THT-shRNA-control-SFFV-GFP (U288).
.4.2. Generation of transduced CCRF-CEM derivatives
The above described lentiviral constructs for gene overexpres-
ion or knock-down were transfected into 293T packaging cells
long with the packaging plasmids pSPAX and pVSV-G (kindly
rovided by Didier Trono) and the lentivirus-containing super-
atants used to transduce CCRF-CEM derivatives. For conditional
LZF/ZBTB16 overexpression, CEM-C7H2-2C8 (which constitu-
ively express rtTA [37]) were transduced and two clonal
ell lines, termed CEM-C7H2-2C8-ZBTB16#19 (ZBTB16#19) and
EM-C7H2-2C8-ZBTB16#58 (ZBTB16#58), derived by limiting
ilution cloning. For knock-down experiments, the lentivirus-
ontaining supernatants were concentrated using poly-ethylene
lycol [46] and used to transduce CEM-C7H2 and ZBTB16#58
ells. Over 85% GFP-expressing bulk populations (if required,
fter enrichment by FACS-sorting) were used for further
xperiments.
.5. Real-time RT-PCR
For PLZF/ZBTB16 mRNA quantiﬁcation by real-time RT-PCR,
0l of diluted cDNA (2ng/l) were added to 50l of Taq-
an Universal MasterMix (Applied Biosystems, Foster City, CA)
nd introduced into microﬂuidic cards containing real-time RT-
CR mixes for human PLZF/ZBTB16 (Hs00232313 m1, Applied
iosystems) and TBP (Hs00427620 m1) as normalization control
ccording to the manufacturer’s guidelines: After equilibration at
T, the channels were ﬁlled with 100l of reaction mix and cen-
rifuged two times for 1minat 1000 rpm. Thereafter, the cardswere
ealed, loaded into the HT7900 real-time machine (Applied Biosys-
ems), and run with a 2-step PCR thermo-protocol that included
n initial 94.5 ◦C step for 10min followed by 40 cycles of 97 ◦C for
5 s alternating with 60 ◦C for 1min. Fluorescence signal intensi-
ieswere readduring the 60 ◦C temperature step. Primary real-time
CR data analysis was performed with SDS software version 2.2.1,
nd further analysis was performed in R (version 2.8). Data from 3
echnically replicated measurements were averaged and normal-
zed to the internal TBP control (Hs.00427620, AppliedBiosystems).
og2-fold change values (M values) were calculated for 3 biologi-
al replicates by comparingnormalized real-timeRT-PCRdata from& Molecular Biology 120 (2010) 218–227
GC-treated samples against data from the corresponding control
samples. M values were averaged for the 3 biological replicates
and p-values were calculated (Student’s t-test) to test against the
null hypothesis of no differential expression (mean M=0). In some
instances (knock-downexperiments, determinationof BimmRNA),
individual real-time RT-PCRs were performed using the same kit
as above for PLZF/ZBTB16 and Hs00197982 m1 for BCL2L11/Bim
(AppliedBiosystems). For individual assays, 20ng transcribedcDNA
was ampliﬁed in TaqMan Universal MasterMix (Applied Biosys-
tems) in 96-well plates (94.5 ◦C for 5min, 40 cycles of 94 ◦C for 15 s
alternating with 60 ◦C for 1min) and ﬂuorescence signal intensi-
ties were read during the 60 ◦C temperature step (iQ5 Multicolor
Real-Time PCR Detection System; Bio-Rad Laboratories Ges.m.b.H.,
Vienna, Austria).
2.6. Affymetrix Exon microarray-based data analysis
To determine PLZF/ZBTB16 response genes, C7H2-2C8-
ZBTB16#19 and #58 cells were cultured in duplicate in the
absence (set A) or presence (set B) of 400ng/ml doxycycline for
2, 6 or 24h. Total RNA was prepared and 1.5g RNA subjected to
expression proﬁling on Exon 1.0 microarrays (total of 24 arrays)
as detailed previously [47]. To assess the effect of PLZF/ZBTB16 on
the GC response, the above cell lines were cultured for 24h in the
absence (set C) or presence (set D) of 200ng/ml doxycycline and
subsequently exposed to 10−8 M dexamethasone for 6 and 24h
and expression-proﬁled as above, resulting in a total of 15 arrays
(one of the four 6h replicates in set C was removed because it
failed quality control).
The bioinformatic analysis of the microarrays was based on a
custom CDF (CEL deﬁnition ﬁle) that allowed generating expres-
sion intensities of transcripts by summarizing the intensity signals
of the individual oligonucleotide probes on the microarray target-
ing a particular transcript. In brief, the sequences of the >5 million
25nt-long oligonucleotide probes on the Affymetrix Exon array
(HuEx-1.0-st v2) were aligned to the genomic DNA sequence from
Ensembl (version 52 36n). For all probes with a single complete
alignment and no additional alignments with up to 1 mismatch,
wedeterminedwhether the alignmentwaswithin the exonbound-
aries of a gene. Probes with sequences with a G/C content >18 were
excluded from the analysis. Exon boundaries and transcript deﬁ-
nitions were taken from the Ensembl core database for all known
protein- and non-coding transcripts and from the ASTD database
(version 1.1) [48] for all potential isoforms of a gene.
Based on the above annotation, a CDF ﬁle was compiled deﬁn-
ing the probes targeting individual transcripts. Probes with no
alignment (allowing 1 mismatch) to the human genome where
deﬁned as “background probes”. The resulting custom CDF con-
tained 1,292,740 probes organized in 131,642 transcript probe sets
corresponding to 28,532 Ensembl genes (49,701 and 88,789 tran-
script probe sets were based on annotations from the Ensembl core
database and the ASTD database, respectively). 72,150 probeswere
deﬁned as “background probes”. Pre-processing and all further
data analyses were performed in R (version 2.8.0) using pack-
ages from Bioconductor (version 2.3) [49] and the custom CDF ﬁle
described above. The raw signal intensities where preprocessed
using the GC-RMA algorithm [15], where the “background probes”
were used to predict the non-speciﬁc binding potential of the
oligonucleotide probes. After pre-processing, the transcript with
the highest variance across all samples was selected for further
analysis as representative for a given gene. The moderated t-test
[50]was then used to assess the signiﬁcance for differential expres-
sion between the compared conditions. The resulting raw p-values
were adjusted for multiple hypothesis testing using Benjamini
and Hochberg’s method for a strong control of the false discovery
rate [51].
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. Results
.1. PLZF/ZBTB16 expression and GC regulation in different
eukemia model systems
We have previously shown that PLZF/ZBTB16 is regulated by
C in numerous patients with ALL, but not in 2 ALL cell lines [7].
o determine whether PLZF/ZBTB16 regulation is restricted to the
n vivo situation or occurs in vitro as well and, if so, whether it
elates to GC sensitivity, we determined PLZF/ZBTB16 regulation
y GC in various in vitro leukemia models using real-time RT-PCR
ig. 1. GC-induced apoptosis and cell cycle arrest in various leukemia cell lines. CCRF-CEM
everse tetracycline-responsive transactivator rtTA), Jurkat (untransfected and transfecte
S4;11, AT-1 and Daudi cells were cultured in the presence of 10−7M dexamethasone (
ubjected to apoptosis (•—•) or cell cycle (G1: dark gray bars; G2/M: light gray bars; S: op
uclei. Shown are mean values ±SD of speciﬁc apoptosis (apoptosis in GC-treated sample
phases of the cell cycle derived from biological triplicates. In some cases, cell cycle det
poptosis and hence were not included in the ﬁgure. The data for all cell lines except 2C8& Molecular Biology 120 (2010) 218–227 221
for PLZF/ZBTB16 and 9 leukemia cell lines treated with 10−7 M
dexamethasone for 2, 6, 12 and 24h in biological triplicates. As
shown in Fig. 1, the extent of GC sensitivity in these cell lines was
markedly different, i.e., untransfected Jurkat and MOLT4 T-ALL cell
lines as well as AT-1 precursor B-ALL and Daudi Burkitt lymphoma
cells were resistant to GC-induced apoptosis, while all others
were GC-sensitive, although with varying kinetics. GR-transfected
Jurkat cells died after 24h exposure to 10−7 M dexamethasone, the
response in CEM-C7H2was delayed about 24h, NALM6 and RS4;11
showed a somewhat slower death response than CEM-C7H2, while
697/EU-3 cells required 96h to reach ∼40% apoptosis. Effects of GC
-C7H2 (C7H2), CEM-C7H2-2C8 (2C8, a C7H2 derivative stably transfected with the
d with rat GR), MOLT4, NALM6, 697 preB-cell recently renamed EU-3 (697/EU-3),
Dex “ + ”) or 0.1% ethanol as vehicle control (Dex “−”) for the indicated time and
en bars) determination using ﬂow cytometric analysis of propidium iodide-stained
s minus apoptosis in corresponding vehicle controls) or mean values of cells in the
erminations did not fulﬁll the required quality requirements due to high degree of
have been reported previously [62].
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Fig. 2. Basal and GC-regulated PLZF/ZBTB16 expression in various leukemia cell
lines. The indicated cell lines were cultured for the indicated times in the pres-
ence of 10−7 M dexamethasone or 0.1% ethanol as vehicle control, and analyzed
for PLZF/ZBTB16 (and TBP as internal control) mRNA expression using quantitative
real-timeRT-PCR for PLZF/ZBTB16. (a) TBP-normalized PLZF/ZBTB16 expression lev-
els in the absence of dexamethasone expressed as minus (−) mean CT (thus, “0”
means CT values equal to those of TBP, negative values indicate increasingly lower
expression). For each biological replicate of the 2h vehicle controls, the CT value for
TBP was subtracted from the corresponding PLZF/ZBTB16 CT value; subsequently,
mean (mean CT) and standard deviations were calculated. (b) GC regulation of
PLZF/ZBTB16 in the indicated cell lines at the indicated time points expressed as
mean M values± standard deviation (M-value of +1 indicates 2-fold up-regulation).
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Fig. 3. Characterizationof T-ALL cell lineswith conditional PLZF/ZBTB16expression.
C7H2-2C8-ZBTB16#19 and #58 cells (expressing PLZF/ZBTB16 in a doxycycline-
dependent manner) were cultured in the presence of increasing concentration of
doxycycline (Dox) for the indicated time and analysed for PLZF/ZBTB16 (and TBP
as internal control) mRNA expression using quantitative real-time RT-PCR (a) or
immunoblottingwith antibodies against PLZF/ZBTB16 and-tubulin as loading con-
trol (b). The real-time RT-PCR data in (a) are expressed as −CT (i.e., CT value of
induction of PLZF/ZBTB16 mRNA that increased up to 50ng/ml andsterisks indicate pBH-values of <0.05 for the corresponding mean M value. In the
97/EU-3 precursor B-cell ALL line, basal PLZF/ZBTB16 levels were below the detec-
ion limit, however, PLZF/ZBTB16 became detectable after GC treatment (not shown
n the graphs).
n cell cycle progression were also determined (Fig. 1) and showed
hat GC-induced apoptosis was frequently preceded or accompa-
ied by an increase of cells in the G1 phase of the cell division cycle,
hereas the cell lines resistant to GC-induced apoptosis were also
esistant to the GC effects on the cell cycle. The notable excep-
ion was AT-1, in which G1 cell cycle arrest was observed in the
omplete absence of apoptosis.
Basal PLZF/ZBTB16 expression levels among these cell lines dif-
ered by close to 3 orders of magnitude (Fig. 2a), reﬂecting the
ituation in children with ALL [7]. Expression ranged from unde-
ectable (697, not shown in Fig. 2) to levels similar to those of
he “housekeeping gene” TBP (MOLT4). PLZF/ZBTB16 expression
howed no correlation with GC sensitivity or T- or precursor B-
ell origin of the cell lines. Signiﬁcant, as deﬁned by an M value
1 (M values correspond to log2 of fold induction) and a p-value
f <0.05, and consistent (i.e., at all time points) GC-induction of
LZF/ZBTB16 was seen in NALM6, RS4;11, AT-1 and GR-transfected
urkats (Fig. 2b). The latter ﬁnding showed that PLZF/ZBTB16 induc-PLZF/ZBTB16 minus CT value of TBP). Shown are mean values ±SD from both cell
lines each analyzed in 3 biological and 3 technical replicates. (b) A representative
dose response at the protein level for the 2, 6 and24h timepoints for the ZBTB16#58
cell line.
tion is criticallydependentonsufﬁcient amountsof functionalGR in
the investigated cell line (Jurkat cells lacking transgenic GR express
low levels ofwild type GR but fail to auto-induce the GR [52]. Taken
together, PLZF/ZBTB16 regulation by GC is not restricted to the in
vivo situation, requires sufﬁcient levels of functionalGRandneither
its regulationnor its expression appear to be clearly correlatedwith
GC sensitivity.
3.2. PLZF/ZBTB16 overexpression reduces, and its knock-down
increases, GC-induced apoptosis
To assess a possible contribution of PLZF/ZBTB16 to the anti-
leukemic GC effects in ALL, we generated 2 stably-transduced
derivatives of the CCRF-CEM T-ALL cell line with conditional
expression of PLZF/ZBTB16, termed CEM-C7H2-2C8-ZBTB16#19
and #58 (ZBTB16#19 and #58), respectively. As revealed by quan-
titative RT-PCR and immunoblotting, PLZF/ZBTB16 mRNA and
protein expression in these cell lines could be controlled by the
addition of the tetracycline analogue doxycycline to the culture
medium(Fig. 3). As little as3.1ng/mldoxycycline led toadetectablereached a plateau thereafter. Interestingly, close tomaximal induc-
tion was seen after only 2h (Fig. 3a, the decrease in expression
levels after 6 and 24h at 3.1 and 12.5ng/ml doxycycline is proba-
bly explained by the half-life of doxycycline in the culture). Similar
M. Wasim et al. / Journal of Steroid Biochemistry & Molecular Biology 120 (2010) 218–227 223
Fig. 4. PLZF/ZBTB16 alone has no effect on cell cycle progression and survival,
but interferes with the anti-leukemic properties of GC. ZBTB16#19 and #58 cells
(expressing PLZF/ZBTB16 in a doxycycline-dependent manner) were cultured in
the absence or presence of 10−7 or 10−8 M dexamethasone (Dex), with and without
200ng/ml doxycycline (Dox) for the indicated time and subjected to apoptosis (a)
or cell division cycle (b) determination using ﬂow cytometric analysis of propidium
iodide-stained nuclei. Shown are mean values ±SD of cells in the subG1 window
(referred to as “apoptosis” in the graph in (a) or mean values of cells in the G1/G0
phase of the cell division cycle (b) derived from biological triplicates of both cell
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Fig. 5. Knock-down of PLZF/ZBTB16 increases GC-elicited cell death. (a) C7H2-2C8-
ZBTB16#58 cells (ZBTB16#58) transduced by recombinant lentiviruses containing
shRNA-expressing constructs targeting exon 7 (shRNA1) or 6 (shRNA2) of
PLZF/ZBTB16 or a control shRNA (shRNA-control) and enriched by FACS-sorting
were culturedwith50ng/mldoxycycline for24handanalysed forPLZF/ZBTB16 (and
TBP as internal control) mRNA expression using quantitative real-time RT-PCR ((a),
left panel) or immunoblottingwith antibodies against PLZF/ZBTB16and-tubulin as
loading control ((a), right panel). ZBTB16 mRNA is expressed as −CT (i.e., CT value
of PLZF/ZBTB16 minus CT value of TBP). Shown are mean values ±SD analyzed in
2 biological and 3 technical replicates. Statistically signiﬁcant (p<0.01) differences
of PLZF/ZBTB16 mRNA expression levels between cells expressing ZBTB16-shRNAs
and controls are indicated by an asterisk. b: CEM-C7H2 cells transduced by the indi-
cated shRNAs as described above were cultured in the absence or presence of 10−7
or 10−8 M dexamethasone (Dex) for 48h and subjected to cell death determination
using ﬂow cytometric analysis of 7-AAD and APC-coupled Annexin-V stained cells.
Shown are mean values ±SD of cells staining positive for Annexin-V and/or 7-AADines (both cell lines gave very similar results and hence were combined in single
raphs). Statistically signiﬁcant (p<0.05) differences between cells treated in the
bsence (+ dox) or presence (− dox) of doxycycline are indicated by an asterisk.
bservations were made at the protein level (Fig. 3b), although
he detection limit was somewhat higher (starting from 12.5ng/ml
oxycycline).
The above clonal cell lineswere thenused to determinewhether
LZF/ZBTB16 expression affects cell survival or cell cycle progres-
ion and/or modulates the anti-leukemic effects of GC. As shown
n Fig. 4, transgenic expression of PLZF/ZBTB16 alone, even at lev-
ls that clearly exceeded those induced by GC, had no detectable
ffect on survival or cell cycle progression. However, it signiﬁcantly
educed the extent of apoptosis induced by 10−7 M and, even more
o, 10−8 Mdexamethasone in this T-ALL in vitromodel (Fig. 4a). GC-
nduced cell cycle arrest was also reduced, but this effect was less
ronounced (Fig. 4b).
Since PLZF/ZBTB16 overexpression provided a protective effect,
e investigated whether knock-down of PLZF/ZBTB16 might
ncrease GC-induced cell death. To this end, we generated 2
entiviral shRNA constructs targeting either exon 7 (shRNA-1)
r 6 (shRNA-2) of PLZF/ZBTB16 and tested them in comparison
ith a negative control shRNA in C7H2-2C8-ZBTB16 cells. A clear,
lthough incomplete, PLZF/ZBTB16knock-downwasobservedboth
n the mRNA and protein levels (Fig. 5a). Next we infected GC-
ensitive CEM-C7H2 cells (the parent of the C7H2-2C8-ZBTB16
ell lines) with recombinant lentiviruses containing these con-
tructs. Since the PLZF/ZBTB16 levels in CEM-C7H2 cells are below
he detection limit of the immunoblotting technique even after
C treatment, we could not verify the knock-down by Western
echnology. On the mRNA level, however, we observed a partial
nock-down in this system as well (5 experiments resulting in a(referred to as “% cell death” in (b) derived from biological triplicates. Statistically
signiﬁcant (p<0.05) differences between cells expressing the indicated shRNAs are
indicated by an asterisk.
mean reduction of 1.6- and 2.1-fold for shRNA-1 and -2, respec-
tively). Corresponding to the extent of knock-down observed with
the 2 constructs, a small, but statistically signiﬁcant increase in cell
death induction was observed (Fig. 5b) further supporting the pro-
tective role of PLZF/ZBTB16 seen in the conditional overexpression
experiments (Fig. 4a).
3.3. PLZF/ZBTB16 protects from GC-induced but not from several
other forms of apoptosis
Next we explored whether the protective effect of PLZF/ZBTB16
was speciﬁc for GC-induced apoptosis or reﬂected a more gen-
eral protective effect against cell death induction. To this end, we
cultured ZBTB16#19 and #58 cells in the presence or absence of
doxycycline (to induce transgenic PLZF/ZBTB16 expression) and
determined the extent of apoptosis elicited by antibodies against
CD95/FAS (representative of an apoptosis inducer via the extrinsic
pathway) or the chemotherapeutics taxol, doxorubicin, or mito-
mycin C (representatives of apoptosis inducers via the intrinsic
pathway). As depicted in Fig. 6, there was no signiﬁcant protec-
tive effect against apoptosis induction by these 4 substances. Thus,
within the limits of the investigated substances, the protective
effect of PLZF/ZBTB16 appeared to be speciﬁc for GC-induced apop-
tosis.
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Fig. 6. PLZF/ZBTB16 does not interfere with anti-CD95/FAS-induced apoptosis or apoptosis and cell cycle arrest induced by mitomycin C, doxorubicin, or taxol. ZBTB16#19
and #58 cells (expressing PLZF/ZBTB16 in a doxycycline-dependent manner) were cultured in the absence or presence of 5, 10 or 20ng/ml anti-CD95/FAS (AF), 0.6 or 3g/ml
mitomycin C, 20 or 100ng/ml doxorubicin (Doxo), 1 or 10g/ml taxol, with and without 200ng/ml doxycycline (Dox) for the indicated time and subjected to apoptosis (a)
or, in the case of treatment with chemotherapeutics, cell cycle (b) determination using ﬂow cytometric analysis of propidium iodide-stained nuclei. Shown are mean values
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.4. PLZF/ZBTB16 alone does not signiﬁcantly change gene
xpression in CCRF-CEM cells but interferes with the GC-mediated
ranscriptional response
To test whether the transcriptional repressor PLZF/ZBTB16
rotects cells from GC-induced apoptosis by directly regulating
xpression of genes involved in cell death/survival decisions, we
ssessed the transcriptional response to transgenic PLZF/ZBTB16
n the above ALL in vitro model by whole genome expression pro-
ling. We cultured 2 biological replicates of ZBTB16#19 and #58
expressing PLZF/ZBTB16 in a tetracycline-dependent manner) in
he absence (“set A”) or presence (“set B”) of 400ng/ml doxycy-
line for 2, 6 and 24h and subjected the corresponding RNAs to
xpression proﬁling on human Exon 1.0 microarrays (Affymetrix,
nc., total of 24 arrays) as indicated in Section 2. Unexpectedly,
owever, apart from PLZF/ZBTB16 itself, which served as an inter-
al control, no signiﬁcant regulations, as deﬁned by a mean M
alue better than ±0.7 and a Benjamini–Hochberg [53] adjusted
-value (pBH) of <0.05, were observed after 2 and 6h of doxycy-
line exposure. After 24h, a single gene reached the above level
f signiﬁcance, i.e., HBEGF (heparin-binding EGF-like growth fac-
or) was repressed with a mean M value of −2.3 and a pBH of
.0299. These data strongly argued against the hypothesis thatted time points derived from biological triplicates of both cell lines (both cell lines
the inhibitory effect of PLZF/ZBTB16 on GC-induced apoptosis was
caused by direct transcriptional regulation of death/survival genes
by PLZF/ZBTB16 (the complete data can be viewed at the GEO web
page, series GSE15820).
Since PLZF/ZBTB16 has previously been shown to interfere
with GC-induction of a transiently transfected, GC-responsive
reporter construct [54], we investigated whether PLZF/ZBTB16
interfered with the transcriptional response to GCs. We deter-
mined Exon array-based expression proﬁles from ZBTB#19 and
#58 cells treated in duplicate with the GC analogue dexametha-
sone together with, or in the absence of, doxycycline. Together
with the expression proﬁles generated further above, we gener-
ated 4 sets of experimental conditions that allowed us to study
the effect of PLZF/ZBTB16 on the transcriptional response to GC.
As explained above, sets “A” and “B” corresponded to data derived
fromZBTB16#19and#58cells cultured induplicates in theabsence
(set A) or presence (set B) of doxycycline for 6 or 24h. Sets “C” and
“D” derived from ZBTB16#19 and #58 cells that were ﬁrst cultured
for 24h in the absence (set C) or presence (set D) of doxycycline to
induce PLZF/ZBTB16 and subsequently exposed to 10−8 M Dex for
6 and 24h. Comparison between sets A (no doxycycline, no dex-
amethasone) and C (no doxycycline, but plus dexamethasone) was
used to identify GC-regulated genes (deﬁned by mean M values
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Fig. 7. PLZF/ZBTB16 interferes with GC regulation of gene expression. To determine
PLZF/ZBTB16 response genes, total RNA from ZBTB16#19 and #58 cells (express-
ing PLZF/ZBTB16 in a doxycycline-dependent manner) cultured in duplicate in the
absence (set A) or presence (set B) of 400ng/ml doxocycline for 6 or 24h was sub-
jected to expression proﬁling on 16 Exon 1.0 microarrays. To assess the effect of
PLZF/ZBTB16 on the GC response, the above cell lines were cultured for 24h in the
absence (set C) or presence (set D) of doxycycline and subsequently exposed to
10−8 M dexamethasone for 6 and 24h and expression-proﬁled as above. Compari-
son between sets A and C identiﬁed GC-regulated genes at 6 and 24h, respectively.
The full lines in the 4 panels show the distribution of the GC-regulated transcripts
with respect to the extent of regulation (mean M) in the absence of doxycycline
(GC/no Dox). The dotted lines represent the regulation of the same transcripts com-
paring sets B andD, i.e., when GC acts in the presence of induced PLZF/ZBTB16 levels
(GC/Dox). The 4 panels depict up- or down-regulations after 6 or 24h, respectively.
Underneath the plots, mean M for all regulations in the corresponding plot ±SD
are shown (|—•—|). In all 4 instances, the extent of regulation was highly signiﬁ-
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Fig. 8. PLZF/ZBTB16 reduces GC-induction of the BH3-only molecule Bim.
ZBTB16#58 cells (expressing PLZF/ZBTB16 in a doxycycline-dependent manner)
were cultured in the absence or presence of 200ng/ml doxycycline (Dox, added
24h prior to dexamethasone) and 10−7 M dexamethasone (Dex) for 24h and anal-
ysed for BCL2L11/BimmRNA expression by real-time RT-PCR (a) or for PLZF/ZBTB16
and BCL2L11/Bimprotein expression by immunoblotting (b). (a) Regulation (CT)
of BCL2L11/Bim mRNA by GC in the presence or absence of doxycycline-induced
PLZF/ZBTB16 expression. For calculation of CT, mean values of TBP-normalized
BCL2L11/Bimexpression (CT)withoutGCwere subtracted from the corresponding
mean values in the presence of GC (thus, a CT of +1 indicates 2-fold up-
regulation). Shown aremean values ±SD of 2 biological replicates assayed 3 times in
3 technical replicates per assay. (b) A representative immunoblot of the same cells
analyzed for PLZF/ZBTB16 (top panel), BCL2L11/Bim (2nd panel: short exposure, i.e.,antly (p0.05) reduced in the presence of doxycycline-induced PLZF/ZBTB16 as
etermined by paired Student’s t-tests.
etter than ±0.7 and pBH<0.05) in this system in the absence of
ransgenic PLZF/ZBTB16. After 6h of GC exposure, 308 down- and
78 up-regulated transcripts fulﬁlled this criterion. After 24h, 929
enes were down- and 717 up-regulated. The regulation of these
enes was then studied after induction of PLZF/ZBTB16 by compar-
ng set B (plus doxycycline, but no dexamethasone)with set D (plus
oxycycline andplusdexamethasone). As shown inFig. 7, the above
C response genes were signiﬁcantly less regulated in the pres-
nce of doxycycline than in its absence, and this was true both for
nduced and repressed genes. The inhibitory effect included genes
uch asBCL2L11/Bim, the inductionofwhichwaspreviously shown
o play a crucial role in GC-induced apoptosis in this model sys-
em [45]. For this functionally relevant gene, the inhibitory effect of
BTB16 overexpression on GC-inductionwas veriﬁed on themRNA
evel by quantitative real-time RT-PCR (Fig. 8a) and on the protein
evel by immunoblotting (Fig. 8b). In conclusion, thedata supported
he hypothesis that PLZF/ZBTB16 reduces GC-induced apoptosis by
nterfering with the hormone’s potential to regulate gene expres-
ion.. Discussion
The transcriptional repressor PLZF/ZBTB16 was one of the most
romising GC-regulated candidate genes for the anti-leukemic30 s; 3rd panel: long exposure, i.e., 4min) and -tubulin as loading control (bottom
panel). The 3 major splice variants of Bim (BimEL, BimL, Bim-S) are indicated in the
long exposure.
effects of GC: It was induced by GC during the in vivo response
to systemic GC monotherapy in childhood ALL and, as shown
in this study, in several leukemia in vitro cell lines. However,
the functional analyses performed in this study revealed that,
at least in the CCRF-CEM T-ALL model, PLZF/ZBTB16 exhibited
a protective effect rather than copying, or contributing to, the
anti-leukemic GC effects. Attempts to understand the molecular
mechanism of this protective effect revealed that this bona ﬁde
transcriptional repressor failed to signiﬁcantly affect gene expres-
sion in the investigated T-ALL model. This ﬁnding was unexpected
because PLZF/ZBTB16 has been reported to cause changes in gene
expression in several systems [26,28,29,33,34]. Even a speciﬁc
search for regulation of some of the most prominent PLZF/ZBTB16
response genes, such as KIT, HOXB7, MYC, CCNA1/cyclin A, PBX1,
CRABPI, BID or RUNX2, failed to provide evidence for transcrip-
tional activity. This included a comparative analysis between the
parental CEM-C7H2 cell line (assayed in biological triplicates on
Exon arrays) [47] and ZBTB16#19 and#58 to assess possible effects
of the small levels of PLZF/ZBTB16 expressed as a consequence
of some leakiness of the tetracycline-regulated expression con-
structs. Several explanations can be offered for this phenomenon:
In most instances [26,28,29,33], non-lymphoid tissues were ana-
lyzed and PLZF/ZBTB16 might require additional co-factors or
post-transcriptional modiﬁcations, such as acetylation [55], that
may not be present in lymphoid cells. The sole expression anal-
ysis in lymphoid cells (Jurkat T-ALL cells [34]) indicated that
PLZF/ZBTB16 altered gene expression only at low cell density and
after 72h of PLZF/ZBTB16 induction. After 24h and at “normal” cell
densities, the ﬁndings in Jurkat cells were compatible with ours.Although apparently inactive as a transcription factor when
tested alone, PLZF/ZBTB16 signiﬁcantly interfered with the tran-
scriptional response to GC (Fig. 7). Although the transgenic
PLZF/ZBTB16 levels were considerably higher than the endoge-
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ous levels in CCRF-CEM cells, similar levels were observed in
ymphoblasts from some childrenwith precursor B-ALL during sys-
emic GC monotherapy [7] (and our unpublished data). Since both
ene inductions and repressions were attenuated in the presence
f PLZF/ZBTB16, and since regulations of many transcription units
ere affected, a general mechanism of action seems likely, such
s sequestration of the activated GR by PLZF/ZBTB16. A more spe-
iﬁc mechanism, such as binding of PLZF/ZBTB16 to the GR on
he promoter and recruitment of transcriptional repressors, would
e expected to interfere with transcriptional induction but not
epressions and, hence, is less likely given that both repression
nd inductions were attenuated. A previous report suggested that
LZF/ZBTB16 might bind to, and inhibit DNA binding of, the GR
54].Mutational analyses revealed that this propertymaps to the C-
erminal portionof PLZF/ZBTB16,which showedparticularly strong
R binding ability. Current analyses in our lab suggest that in at
east in one of our cell line systems, GC might speciﬁcally induce
xons3–7 (presumablyviaalternativepromoterusage) that encode
he above-mentioned particularly active portion of PLZF/ZBTB16.
A question of considerable interest is whether PLZF/ZBTB16
s a direct target of the GC receptor (GR). Previous studies using
LZF/ZBTB16 promoter-driven reporter assays in primary human
ndometrial stromal and myometrial smooth muscle cells, where
LZF/ZBTB16 is regulated by progesterone and GC, suggested that
t is not [56]. We have performed Affymetrix promoter tiling array-
ased Chip-on-CHIP analyses using CCRF-CEM and NALM6 cells
nd failed to ﬁnd evidence of direct binding of the GR to the
LZF/ZBTB16 promoter (Rainer et al., in preparation). However,
oth negative evidences are limited by the sequences analyzed, i.e.,
he reporter study covered an ∼5kb region upstream and the pro-
oter tiling array 7.5 kb upstream and 2.5 kb downstream of the
utative start site.
In conclusion, we report that the transcriptional repressor
LZF/ZBTB16, one of the most promising GC-regulated candidate
enes for the anti-leukemic effects of GC, did not contribute to, but
ather protected CCRF-CEM leukemia cells from, the anti-leukemic
C effects. Although counterintuitive on ﬁrst sight, induction
f pro-survival signaling by GC in the course of an apoptotic
esponse is not unheard of. Thus, we observed repression of the
ro-apoptotic BH3-only molecule PMAIP1/Noxa in children and
xperimental systems of GC-induced apoptosis [45] and could
how that this regulatory event is functionally relevant, since it
nterfereswith the kinetics of, and sensitivity to, GC-induced apop-
osis [57]. Since GC are known to mediate pro-survival effects in
ertain systems, such as erythroblasts [58], neutrophils [59,60] or
olid tumors [61], theGC responsemay inherently be complex, con-
aining pro- and anti-apoptotic components. The cellular context
ay then determine which of the 2 opposing responses prevails.
he growing understanding of this complexity might eventually
llow speciﬁc interference with the pro-survival component of the
esponse, thereby increasing the efﬁcacy of GC in the therapy of
ymphoid malignancies.
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